October 13, 2025 /
Click above image to listen
David Jones, MD, principal medical director of multiple sclerosis at Genentech, highlights how pediatric MS differs from adult-onset disease, with higher relapse rates and unique treatment challenges. He discusses data supporting Ocrevus for young patients and stresses the importance of FDA approval in building confidence among families and payers. For more from David Jones, read our article here.
Transcript
Pediatric MS is different than adult MS. The disease tends to be more aggressive on natural history relapse rate and MRI activity are much higher.
=========================
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY
